Grufity logoGrufity logo
StocksFundsSearch Filings

STAAR Surgical Co Stock Research

STAA

57.70USD-0.08(-0.14%)Market Closed

Market Summary

USD57.70-0.08
Market Closed
-0.14%

STAA Alerts

STAA Stock Price

STAA RSI Chart

STAA Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

87.64

Price/Sales (Trailing)

9.48

EV/EBITDA

62.35

Price/Free Cashflow

166.61

STAA Price/Sales (Trailing)

STAA Profitability

EBT Margin

16.02%

Return on Equity

11.67%

Return on Assets

9.34%

Free Cashflow Yield

0.6%

STAA Fundamentals

STAA Revenue

Revenue (TTM)

294.7M

Revenue Y/Y

16.34%

Revenue Q/Q

14.81%

STAA Earnings

Earnings (TTM)

31.9M

Earnings Y/Y

-71.78%

Earnings Q/Q

-53.7%

Price Action

52 Week Range

46.36112.27
(Low)(High)

Last 7 days

-2.6%

Last 30 days

-15.8%

Last 90 days

-3.6%

Trailing 12 Months

-11.4%

STAA Financial Health

Current Ratio

6.03

STAA Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

0.63

Peers (Alternatives to STAAR Surgical)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
171.1B
30.9B
-4.16% -10.76%
24.67
5.53
2.20% 7.40%
111.4B
30.8B
-8.29% -14.72%
27.36
3.62
-3.19% -17.32%
110.8B
19.0B
-5.21% 22.61%
46.98
6.01
8.73% 30.37%
109.4B
6.4B
3.09% 43.51%
83.37
17.01
8.89% -20.19%
17.6B
-
-2.11% 9.04%
46.93
5.79
13.20% -60.04%
MID-CAP
7.2T
557.2M
0.46% 77.48%
82.2K
16.8K
86.42% 730.06%
12.0B
884.6M
11.70% 122.44%
1.8K
13.54
13.08% 200.12%
5.9B
1.1B
-2.60% -14.42%
34.14
5.75
11.20% 53.04%
3.2B
430.0M
-15.34% -20.02%
-30.76
7.49
26.13% 15.73%
2.8B
294.7M
-15.81% -11.38%
87.64
9.48
21.32% 9.45%
SMALL-CAP
1.2B
150.7M
-26.10% -4.98%
-21.96
7.98
40.31% 1.80%
1.2B
814.3M
-15.33% -12.83%
25.98
1.42
6.96% 121.89%
1.0B
163.2M
34.38% 72.90%
-6.86
6.15
17.84% -885.82%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for STAAR Surgical

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue3.6%295284279262243
Gross Profit3.7%232223219203189
  S&GA Expenses9.8%197180168159151
  R&D Expenses6.6%38.0036.0035.0034.0034.00
EBITDA-1.1%50.0051.0045.0040.00-
EBITDA Margin-2.8%0.18*0.18*0.17*0.17*-
Earnings Before Taxes-14.9%39.0046.0047.0041.0037.00
EBT Margin-3.9%0.16*0.17*0.16*0.15*-
Net Income-17.8%32.0039.0038.0034.0029.00
Net Income Margin0.6%0.14*0.14*0.13*0.12*-
Free Cahsflow-21.6%18.0022.0024.0019.00-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets1.0%419415395376351
  Current Assets0.4%313312297296274
    Cash Equivalents4.0%90.0086.00129202193
  Net PPE5.0%53.0051.0048.0043.0040.00
  Goodwill0%2.002.002.002.002.00
Liabilities-3.3%80.0083.0075.0077.0075.00
  Current Liabilities-9.0%47.0052.0045.0047.0041.00
Shareholder's Equity2.0%339332320299276
  Retained Earnings3.7%-69.92-72.64-78.49-88.75-101
  Additional Paid-In Capital1.3%409404398387379
Accumulated Depreciation2.6%37.0036.0035.00--
Shares Outstanding0.2%48.0048.0048.0048.0048.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-1.4%35.0036.0041.0039.0033.00
  Share Based Compensation10.7%23.0020.0019.0017.0015.00
Cashflow From Investing8.0%-143-156-114-15.77-14.02
Cashflow From Financing-27.2%6.008.008.007.0013.00

Risks for STAA

What is the probability of a big loss on STAA?

93.5%


Probability that STAAR Surgical stock will be more than 20% underwater in next one year

88.8%


Probability that STAAR Surgical stock will be more than 30% underwater in next one year.

54.6%


Probability that STAAR Surgical stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does STAA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if STAAR Surgical was unfortunately bought at previous high price.

Drawdowns

Returns for STAA

Cumulative Returns on STAA

20.6%


10-Year Cumulative Returns

39.5%


7-Year Cumulative Returns

13.8%


5-Year Cumulative Returns

13.3%


3-Year Cumulative Returns

What are the long-term rolling returns for STAA?

FIve years rolling returns for STAAR Surgical.

Annualized Returns

Which funds bought or sold STAA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-30
Aspire Private Capital, LLC
unchanged
-
23,115
95,925
0.03%
2023-05-26
ProShare Advisors LLC
reduced
-13.76
65,237
544,278
-%
2023-05-23
ROYCE & ASSOCIATES LP
reduced
-24.45
-13,077
2,765,840
0.03%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-4.06
347,356
1,663,280
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-0.85
953,905
4,069,900
-%
2023-05-22
Raleigh Capital Management Inc.
sold off
-100
-3,155
-
-%
2023-05-18
JPMORGAN CHASE & CO
added
14.13
3,703,000
11,055,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-13.07
407,000
3,209,000
-%
2023-05-17
Advisory Services Network, LLC
reduced
-91.7
-104,191
12,790
-%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
added
2.08
-100,794
237,846
-%

1–10 of 39

Latest Funds Activity

Are funds buying STAA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own STAA
No. of Funds

STAAR Surgical News

MarketBeat
Advisory Research Inc. Sells 39905 Shares of STAAR Surgical ....
MarketBeat,
2 days ago
The Motley Fool
Orange County Business Journal
Larger Health Firms Report Mixed Q1 Results.
Orange County Business Journal,
17 days ago
Manistee News Advocate
Staar Surgical: Q1 Earnings Snapshot.
Manistee News Advocate,
30 days ago
Yahoo Finance

Schedule 13G FIlings of STAAR Surgical

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
11.01%
5,306,915
SC 13G/A
Jan 23, 2023
blackrock inc.
11.9%
5,738,044
SC 13G/A
Jan 19, 2023
baillie gifford & co
10.87%
5,240,456
SC 13G/A
Feb 14, 2022
palo alto investors lp
2.40%
1,140,511
SC 13G/A
Feb 10, 2022
vanguard group inc
10.44%
4,970,324
SC 13G/A
Jan 27, 2022
blackrock inc.
11.8%
5,622,956
SC 13G/A
Jan 26, 2022
baillie gifford & co
11.62%
5,529,868
SC 13G/A
Jan 25, 2022
blackrock inc.
11.8%
5,622,956
SC 13G/A
Oct 01, 2021
broadwood partners, l.p.
18.1%
0
SC 13D/A
Sep 10, 2021
vanguard group inc
10.10%
4,787,522
SC 13G/A

STAA Fair Value

Show Fair-Value

Recent SEC filings of STAAR Surgical

View All Filings
Date Filed Form Type Document
May 09, 2023
4
Insider Trading
May 09, 2023
4
Insider Trading
May 04, 2023
8-K
Current Report
May 03, 2023
10-Q
Quarterly Report
May 03, 2023
8-K
Current Report
Apr 26, 2023
ARS
ARS
Apr 26, 2023
DEF 14A
DEF 14A
Apr 26, 2023
DEFA14A
DEFA14A
Mar 29, 2023
3
Insider Trading
Mar 29, 2023
3
Insider Trading

Latest Insider Trading transactions for STAA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-08
Foust Warren
acquired
-
-
20,331
chief operating officer
2023-05-08
Michna Magda
acquired
-
-
14,047
chief clinical, regulatory,
2023-03-20
Francese James E
sold (taxes)
-49,469
62.07
-797
sr. vp, comm. ops., na, apac
2023-03-20
Gesten Samuel J
sold (taxes)
-55,366
62.07
-892
chief legal officer
2023-03-20
Holliday Keith
sold (taxes)
-56,297
62.07
-907
chief technology officer
2023-03-20
Barnes Scott D
sold (taxes)
-56,545
62.07
-911
chief medical officer
2023-03-17
Holliday Keith
sold
-51,001
61.97
-823
chief technology officer
2023-03-10
Barnes Scott D
sold (taxes)
-16,139
56.63
-285
chief medical officer
2023-03-10
Barnes Scott D
acquired
-
-
10,555
chief medical officer
2023-03-10
Holliday Keith
sold (taxes)
-16,082
56.63
-284
chief technology officer

1–10 of 50

Caren L. Mason
810
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAA Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Apr. 01, 2022
Income Statement [Abstract]  
Net sales$ 73,528$ 63,200
Cost of sales15,96613,936
Gross profit57,56249,264
Selling, general and administrative expenses:  
General and administrative18,09811,940
Selling and marketing26,35417,270
Research and development10,3107,941
Total selling, general and administrative expenses54,76237,151
Operating income2,80012,113
Other income (expense), net:  
Interest income (expense), net1,822(6)
Gain (loss) on foreign currency transactions34(915)
Royalty income 273
Other income, net6362
Total other income (expense), net1,919(586)
Income before income taxes4,71911,527
Provision for income taxes2,0091,925
Net income$ 2,710$ 9,602
Net income per share:  
Basic$ 0.06$ 0.20
Diluted$ 0.05$ 0.19
Weighted average shares outstanding:  
Basic48,24747,755
Diluted49,50049,288

STAA Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 30, 2022
Current assets:  
Cash and cash equivalents$ 89,968$ 86,480
Investments available for sale113,879125,159
Accounts receivable trade, net of allowance for credit losses of $43 and $20, respectively63,49462,447
Inventories, net27,80824,161
Prepayments, deposits and other current assets17,72213,476
Total current assets312,871311,723
Investments available for sale13,44513,902
Property, plant and equipment, net53,45350,921
Finance lease right-of-use assets, net303342
Operating lease right-of-use assets, net31,18230,270
Intangible assets, net165173
Goodwill1,7861,786
Deferred income taxes4,7444,824
Other assets956957
Total assets418,905414,898
Current liabilities:  
Accounts payable9,10211,576
Obligations under finance leases171169
Obligations under operating leases3,5383,524
Allowance for sales returns5,3035,706
Other current liabilities28,94930,741
Total current liabilities47,06351,716
Obligations under finance leases167210
Obligations under operating leases28,03027,136
Deferred income taxes1,3691,489
Asset retirement obligations218220
Pension liability3,1341,935
Total liabilities79,98182,706
Commitments and contingencies
Stockholders’ equity:  
Common stock, $0.01 par value; 60,000 shares authorized: 48,331 and 48,212 shares issued and outstanding at March 31, 2023 and December 30, 2022, respectively483482
Additional paid-in capital409,303404,189
Accumulated other comprehensive gain (loss)(937)156
Accumulated deficit(69,925)(72,635)
Total stockholders’ equity338,924332,192
Total liabilities and stockholders’ equity$ 418,905$ 414,898